Pharvaris (NASDAQ:PHVS) Insider Sells $453,600.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 15,000 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the completion of the sale, the insider owned 66,083 shares in the company, valued at $1,998,349.92. This represents a 18.50% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Peng Lu also recently made the following trade(s):

• On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The shares were sold at an average price of $30.06, for a total transaction of $112,213.98.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $210,380.05.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $29.44 on Monday. Pharvaris N.V. has a 52 week low of $14.59 and a 52 week high of $31.14. The company’s fifty day moving average is $27.62 and its 200-day moving average is $26.09. The company has a market capitalization of $1.93 billion, a PE ratio of -8.74 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). On average, analysts forecast that Pharvaris N.V. will post -3.19 EPS for the current year.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six‑figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near‑term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director’s Sale Matters Less Than What’s Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ≈$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ≈$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ≈$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Analysts Set New Price Targets

Several research analysts recently issued reports on PHVS shares. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday, March 3rd. Wolfe Research started coverage on shares of Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target on the stock. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Wall Street Zen downgraded shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $42.73.

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of PHVS. Geode Capital Management LLC increased its stake in shares of Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after acquiring an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after acquiring an additional 1,695 shares during the last quarter. Amundi increased its stake in shares of Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after acquiring an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Pharvaris by 19.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after acquiring an additional 7,879 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.